Wells Fargo’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-151,406
| Closed | -$621K | – | 7998 |
|
|
2022
Q1 | $621K | Sell |
151,406
-55,111
| -27% | -$200K | ﹤0.01% | 4253 |
|
|
2021
Q4 | $737K | Sell |
206,517
-456,910
| -69% | -$1.6M | ﹤0.01% | 4365 |
|
|
2021
Q3 | $2.42M | Buy |
663,427
+112,719
| +20% | +$456K | ﹤0.01% | 3494 |
|
|
2021
Q2 | $2.4M | Buy |
550,708
+212,405
| +63% | +$865K | ﹤0.01% | 3524 |
|
|
2021
Q1 | $1.39M | Sell |
338,303
-94,075
| -22% | -$408K | ﹤0.01% | 4012 |
|
|
2020
Q4 | $1.73M | Buy |
432,378
+49,974
| +13% | +$162K | ﹤0.01% | 3607 |
|
|
2020
Q3 | $1.03M | Sell |
382,404
-15,019
| -4% | -$41.6K | ﹤0.01% | 3840 |
|
|
2020
Q2 | $1.09M | Buy |
397,423
+93,095
| +31% | +$260K | ﹤0.01% | 3741 |
|
|
2020
Q1 | $717K | Buy |
304,328
+125,440
| +70% | +$427K | ﹤0.01% | 3765 |
|
|
2019
Q4 | $841K | Buy |
178,888
+94,499
| +112% | +$387K | ﹤0.01% | 3978 |
|
|
2019
Q3 | $282K | Sell |
84,389
-117,507
| -58% | -$387K | ﹤0.01% | 4757 |
|
|
2019
Q2 | $664K | Sell |
201,896
-54,412
| -21% | -$157K | ﹤0.01% | 4181 |
|
|
2019
Q1 | $777K | Buy |
256,308
+19,889
| +8% | +$64.5K | ﹤0.01% | 4056 |
|
|
2018
Q4 | $644K | Buy |
236,419
+150,450
| +175% | +$496K | ﹤0.01% | 4177 |
|
|
2018
Q3 | $289K | Sell |
85,969
-1,910,952
| -96% | -$5.9M | ﹤0.01% | 4798 |
|
|
2018
Q2 | $5.15M | Buy |
1,996,921
+63,452
| +3% | +$158K | ﹤0.01% | 2653 |
|
|
2018
Q1 | $4.25M | Buy |
1,933,469
+342,062
| +21% | +$770K | ﹤0.01% | 2767 |
|
|
2017
Q4 | $3.17M | Buy |
1,591,407
+255,501
| +19% | +$556K | ﹤0.01% | 2997 |
|
|
2017
Q3 | $4.33M | Buy |
1,335,906
+294,810
| +28% | +$910K | ﹤0.01% | 2652 |
|
|
2017
Q2 | $3.35M | Buy |
1,041,096
+273,496
| +36% | +$775K | ﹤0.01% | 2767 |
|
|
2017
Q1 | $2.18M | Buy |
767,600
+136,600
| +22% | +$329K | ﹤0.01% | 3133 |
|
|
2016
Q4 | $1.47M | Buy |
631,000
+222,000
| +54% | +$423K | ﹤0.01% | 3404 |
|
|
2016
Q3 | $687K | Buy |
409,000
+57,500
| +16% | +$70.4K | ﹤0.01% | 3768 |
|
|
2016
Q2 | $369K | Buy |
351,500
+147,762
| +73% | +$143K | ﹤0.01% | 4074 |
|
|
2016
Q1 | $176K | Buy |
203,738
+10,322
| +5% | +$9.99K | ﹤0.01% | 4482 |
|
|
2015
Q4 | $234K | Sell |
193,416
-15,459
| -7% | -$21.5K | ﹤0.01% | 4358 |
|
|
2015
Q3 | $355K | Sell |
208,875
-56,984
| -21% | -$112K | ﹤0.01% | 4160 |
|
|
2015
Q2 | $553K | Buy |
265,859
+74,947
| +39% | +$182K | ﹤0.01% | 4022 |
|
|
2015
Q1 | $517K | Buy |
190,912
+36,997
| +24% | +$93.9K | ﹤0.01% | 3930 |
|
|
2014
Q4 | $396K | Buy |
153,915
+18,043
| +13% | +$40.5K | ﹤0.01% | 4068 |
|
|
2014
Q3 | $249K | Sell |
135,872
-26,934
| -17% | -$58.7K | ﹤0.01% | 4254 |
|
|
2014
Q2 | $435K | Buy |
162,806
+11,306
| +7% | +$34K | ﹤0.01% | 3989 |
|
|
2014
Q1 | $530K | Hold |
151,500
| – | – | ﹤0.01% | 3839 |
|
|
2013
Q4 | $677K | Buy |
151,500
+18,000
| +13% | +$73.3K | ﹤0.01% | 3650 |
|
|
2013
Q3 | $542K | Buy |
133,500
+2,000
| +2% | +$8.73K | ﹤0.01% | 3720 |
|
|
2013
Q2 | $547K | Buy |
+131,500
| New | +$508K | ﹤0.01% | 3639 |
|
Other funds holding ATRS
Wells Fargo's ATRS Position: Q2 2022 in Review
Wells Fargo sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 151,406 shares — an estimated $621K sold.
Wells Fargo first reported a position in ATRS in Q2 2013 and held it in 36 quarters. The position peaked at $5.15M in Q2 2018. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Wells Fargo reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Wells Fargo sold 151,406 Antares Pharma, Inc. shares in Q2 2022, an estimated $621K.
- Wells Fargo first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 36 quarters.
- Wells Fargo's Antares Pharma, Inc. position peaked at $5.15M in Q2 2018.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Wells Fargo's 13F filing for Q2 2022, filed 12 Aug 2022.